#France #UroMems #Grenoble #UroActive #Stress Incontinence

UroMems Breakthrough Study Results

UroMems, a leading global innovator in challenging medical conditions, proudly announces the successful results of its pioneering clinical feasibility study involving its UroActive® smart implant designed for women suffering from stress urinary incontinence (SUI). This landmark research showcases the potential for a transformative shift in therapy options for millions of women globally.

The recent findings, which will be showcased for the first time at the renowned SUFU Winter Meeting in Palm Springs, California, at the end of February 2025, reveal that all participants in this unprecedented study reached their six-month primary endpoint. This achievement signals hope for those struggling with SUI, a condition that disrupts daily life and significantly impairs quality of life.

“We are overjoyed to introduce this groundbreaking technology to the medical community,” said Hamid Lamraoui, co-founder and CEO of UroMems. He emphasized the urgency of addressing the high prevalence of SUI in women, underlining the desperate need for effective solutions currently absent in the market. “Through our study, we had 12 participants, and each of the female patients has described a renewed sense of liberty in their daily lives.”

The feasibility study, which employed a prospective multicenter clinical approach, demonstrated that the UroActive system—a first-of-its-kind automated artificial urinary sphincter—successfully accommodated the unique physiology of female patients. It is particularly significant that all six women included in the trial had their devices successfully implanted for at least seven months, with one patient now approaching two years. Throughout this period, operational integrity was maintained with no requirement for revisions or removals.

Participants expressed profound appreciation for the UroActive device, with one participant stating, “I am living again. It's night and day,” echoing the sentiment of another who declared, “It's fabulous! Thank you for this innovative product.” These testimonials provide not only qualitative feedback but also underscore the human impact of SUI and the dire need for innovative solutions.

The UroActive implant is cutting-edge, utilizing a MyoElectroMechanical System (MEMS) that circumvents the urethral duct and activates based on the patient’s activities, eliminating cumbersome manual controls. Its design aims to enhance patient comfort and significantly improve their quality of life in comparison to traditional alternatives.

UroMems has made tremendous strides recently in developing the product, including securing substantial funding of $47 million. This fresh capital followed compelling trial results from the initial cohort, which successfully demonstrated not only the clinical feasibility but also significant potential for widespread application in addressing SUI.

With SUI affecting approximately 40 million individuals in the U.S. alone and nearly 90 million in Europe, the implications of UroMems’ findings are profound. This condition often leads to a cycle of emotional distress, social stigma, and diminished self-worth, reinforcing the severity of the issue.

As UroMems pioneers this effort, the promising results from the feasibility study mark a critical milestone in the journey towards providing viable therapeutic alternatives for those afflicted by SUI. The UroActive smart implant, though not yet commercially available in the U.S. or EU, represents the future of urinary incontinence treatments.

In conclusion, UroMems’ innovative technology platform, fortified by over 150 patents, aims to enhance safety, performance, and patient experience—all essential as surgeons seek effective treatments for urinary incontinence. Support from the European Innovation Council and the France 2030 initiative further validates UroMems’ commitment to improving life quality for patients grappling with SUI.

For further details and updates, consider visiting UroMems official website.